HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells
Meimei Shan, Per Johan Klasse, Kaustuv Banerjee, Antu K Dey, Sai Prasad N Iyer, Robert Dionisio, Dustin Charles, Lila Campbell-Gardener, William C Olson, Rogier W Sanders, John P Moore, Meimei Shan, Per Johan Klasse, Kaustuv Banerjee, Antu K Dey, Sai Prasad N Iyer, Robert Dionisio, Dustin Charles, Lila Campbell-Gardener, William C Olson, Rogier W Sanders, John P Moore
Abstract
The human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein gp120 is a vaccine immunogen that can signal via several cell surface receptors. To investigate whether receptor biology could influence immune responses to gp120, we studied its interaction with human, monocyte-derived dendritic cells (MDDCs) in vitro. Gp120 from the HIV-1 strain JR-FL induced IL-10 expression in MDDCs from 62% of donors, via a mannose C-type lectin receptor(s) (MCLR). Gp120 from the strain LAI was also an IL-10 inducer, but gp120 from the strain KNH1144 was not. The mannose-binding protein cyanovirin-N, the 2G12 mAb to a mannose-dependent gp120 epitope, and MCLR-specific mAbs inhibited IL-10 expression, as did enzymatic removal of gp120 mannose moieties, whereas inhibitors of signaling via CD4, CCR5, or CXCR4 were ineffective. Gp120-stimulated IL-10 production correlated with DC-SIGN expression on the cells, and involved the ERK signaling pathway. Gp120-treated MDDCs also responded poorly to maturation stimuli by up-regulating activation markers inefficiently and stimulating allogeneic T cell proliferation only weakly. These adverse reactions to gp120 were MCLR-dependent but independent of IL-10 production. Since such mechanisms might suppress immune responses to Env-containing vaccines, demannosylation may be a way to improve the immunogenicity of gp120 or gp140 proteins.
Conflict of interest statement
Competing interests. The authors have declared that no competing interests exist.
Figures
References
- Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol. 2004;5:233–236.
- Pantophlet R, Burton DR. GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol. 2006;24:739–769.
- Zwick MB. The membrane-proximal external region of HIV-1 gp41: a vaccine target worth exploring. Aids. 2005;19:1725–1737.
- McMichael AJ. HIV vaccines. Annu Rev Immunol. 2006;24:227–255.
- Connor RI, Korber BT, Graham BS, Hahn BH, Ho DD, et al. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol. 1998;72:1552–1576.
- Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005;191:654–665.
- Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis. 2005;191:666–677.
- Graham BS, McElrath MJ, Connor RI, Schwartz DH, Gorse GJ, et al. Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group and the Correlates of HIV Immune Protection Group. J Infect Dis. 1998;177:310–319.
- Grundner C, Pancera M, Kang JM, Koch M, Sodroski J, et al. Factors limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins. Virology. 2004;330:233–248.
- Wright PF, Mestecky J, McElrath MJ, Keefer MC, Gorse GJ, et al. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein. J Infect Dis. 2004;189:1221–1231.
- Daly LM, Johnson PA, Donnelly G, Nicolson C, Robertson J, et al. Innate IL-10 promotes the induction of Th2 responses with plasmid DNA expressing HIV gp120. Vaccine. 2005;23:963–974.
- Gorse GJ, Corey L, Patel GB, Mandava M, Hsieh RH, et al. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses. 1999;15:115–132.
- Abbas A, Vasilescu A, Do H, Hendel H, Maachi M, et al. Analysis of IGG and IGG4 in HIV-1 seropositive patients and correlation with biological and genetic markers. Biomed Pharmacother. 2005;59:38–46.
- Martinez V, Costagliola D, Bonduelle O, N'go N, Schnuriger A, et al. Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. J Infect Dis. 2005;191:2053–2063.
- Ngo-Giang-Huong N, Candotti D, Goubar A, Autran B, Maynart M, et al. HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression. AIDS Res Hum Retroviruses. 2001;17:1435–1446.
- Klasse PJ, Moore JP. Is there enough gp120 in the body fluids of HIV-1-infected individuals to have biologically significant effects? Virology. 2004;323:1–8.
- Ameglio F, Capobianchi MR, Castilletti C, Cordiali Fei P, Fais S, et al. Recombinant gp120 induces IL-10 in resting peripheral blood mononuclear cells; correlation with the induction of other cytokines. Clin Exp Immunol. 1994;95:455–458.
- Borghi P, Fantuzzi L, Varano B, Gessani S, Puddu P, et al. Induction of interleukin-10 by human immunodeficiency virus type 1 and its gp120 protein in human monocytes/macrophages. J Virol. 1995;69:1284–1287.
- Fantuzzi L, Purificato C, Donato K, Belardelli F, Gessani S. Human immunodeficiency virus type 1 gp120 induces abnormal maturation and functional alterations of dendritic cells: a novel mechanism for AIDS pathogenesis. J Virol. 2004;78:9763–9772.
- Gessani S, Borghi P, Fantuzzi L, Varano B, Conti L, et al. Induction of cytokines by HIV-1 and its gp120 protein in human peripheral blood monocyte/macrophages and modulation of cytokine response during differentiation. J Leukoc Biol. 1997;62:49–53.
- Granelli-Piperno A, Golebiowska A, Trumpfheller C, Siegal FP, Steinman RM. HIV-1-infected monocyte-derived dendritic cells do not undergo maturation but can elicit IL-10 production and T cell regulation. Proc Natl Acad Sci U S A. 2004;101:7669–7674.
- Mellado M, Llorente M, Rodriguez-Frade JM, Lucas P, Martinez C, et al. HIV-1 envelope protein gp120 triggers a Th2 response in mice that shifts to Th1 in the presence of human growth hormone. Vaccine. 1998;16:1111–1115.
- Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683–765.
- Taoufik Y, Lantz O, Wallon C, Charles A, Dussaix E, et al. Human immunodeficiency virus gp120 inhibits interleukin-12 secretion by human monocytes: an indirect interleukin-10-mediated effect. Blood. 1997;89:2842–2848.
- Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol. 2002;76:7293–7305.
- Botos I, O'Keefe BR, Shenoy SR, Cartner LK, Ratner DM, et al. Structures of the complexes of a potent anti-HIV protein cyanovirin-N and high mannose oligosaccharides. J Biol Chem. 2002;277:34336–34342.
- Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1–>2 mannose residues on the outer face of gp120. J Virol. 2002;76:7306–7321.
- He B, Qiao X, Klasse PJ, Chiu A, Chadburn A, et al. HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J Immunol. 2006;176:3931–3941.
- Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response. Annu Rev Immunol. 2002;20:55–72.
- Yi AK, Yoon JG, Yeo SJ, Hong SC, English BK, et al. Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production: central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated Th1 response. J Immunol. 2002;168:4711–4720.
- Puig-Kroger A, Relloso M, Fernandez-Capetillo O, Zubiaga A, Silva A, et al. Extracellular signal-regulated protein kinase signaling pathway negatively regulates the phenotypic and functional maturation of monocyte-derived human dendritic cells. Blood. 2001;98:2175–2182.
- Caparros E, Munoz P, Sierra-Filardi E, Serrano-Gomez D, Puig-Kroger A, et al. DC-SIGN ligation on dendritic cells results in ERK and PI3K activation and modulates cytokine production. Blood. 2006;107:3950–3958.
- Gurney KB, Elliott J, Nassanian H, Song C, Soilleux E, et al. Binding and transfer of human immunodeficiency virus by DC-SIGN+ cells in human rectal mucosa. J Virol. 2005;79:5762–5773.
- Gramberg T, Caminschi I, Wegele A, Hofmann H, Pohlmann S. Evidence that multiple defects in murine DC-SIGN inhibit a functional interaction with pathogens. Virology. 2006;345:482–491.
- Park CG, Takahara K, Umemoto E, Yashima Y, Matsubara K, et al. Five mouse homologues of the human dendritic cell C-type lectin, DC-SIGN. Int Immunol. 2001;13:1283–1290.
- Reading PC, Miller JL, Anders EM. Involvement of the mannose receptor in infection of macrophages by influenza virus. J Virol. 2000;74:5190–5197.
- Thielens NM, Tacnet-Delorme P, Arlaud GJ. Interaction of C1q and mannan-binding lectin with viruses. Immunobiology. 2002;205:563–574.
- Turville S, Wilkinson J, Cameron P, Dable J, Cunningham AL. The role of dendritic cell C-type lectin receptors in HIV pathogenesis. J Leukoc Biol. 2003;74:710–718.
- Gringhuis SI, den Dunnen J, Litjens M, van Het Hof B, van Kooyk Y, et al. C-type lectin DC-SIGN modulates Toll-like receptor signaling via Raf-1 kinase-dependent acetylation of transcription factor NF-kappaB. Immunity. 2007;26:605–616.
- Kurzai O, Schmitt C, Claus H, Vogel U, Frosch M, et al. Carbohydrate composition of meningococcal lipopolysaccharide modulates the interaction of Neisseria meningitidis with human dendritic cells. Cell Microbiol. 2005;7:1319–1334.
- Lin MT, Storer B, Martin PJ, Tseng LH, Grogan B, et al. Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease following hematopoietic cell transplantation: synergism between IL-10 genotype of patient and IL-10 receptor beta genotype of donor. Blood. 2005;106:3995–4001.
- Wilson JN, Rockett K, Jallow M, Pinder M, Sisay-Joof F, et al. Analysis of IL10 haplotypic associations with severe malaria. Genes Immun. 2005;6:462–466.
- Nabatov AA, van Montfort T, Geijtenbeek TB, Pollakis G, Paxton WA. Interaction of HIV-1 with dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin-expressing cells is influenced by gp120 envelope modifications associated with disease progression. Febs J. 2006;273:4944–4958.
- Beignon AS, McKenna K, Skoberne M, Manches O, DaSilva I, et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest. 2005;115:3265–3275.
- Meier A, Alter G, Frahm N, Sidhu H, Li B, et al. MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded toll-like receptor ligands. J Virol. 2007;81:8180–8191.
- Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol. 2006;7:131–137.
- Williams MA, Trout R, Spector SA. HIV-1 gp120 modulates the immunological function and expression of accessory and co-stimulatory molecules of monocyte-derived dendritic cells. J Hematother Stem Cell Res. 2002;11:829–847.
- Smed-Sorensen A, Lore K, Walther-Jallow L, Andersson J, Spetz AL. HIV-1-infected dendritic cells up-regulate cell surface markers but fail to produce IL-12 p70 in response to CD40 ligand stimulation. Blood. 2004;104:2810–2817.
- Megiovanni AM, Sanchez F, Gluckman JC, Rosenzwajg M. Double-stranded RNA stimulation or CD40 ligation of monocyte-derived dendritic cells as models to study their activation and maturation process. Eur Cytokine Netw. 2004;15:126–134.
- Hodges A, Sharrocks K, Edelmann M, Baban D, Moris A, et al. Activation of the lectin DC-SIGN induces an immature dendritic cell phenotype triggering Rho-GTPase activity required for HIV-1 replication. Nat Immunol. 2007;8:569–577.
- Chieppa M, Bianchi G, Doni A, Del Prete A, Sironi M, et al. Cross-linking of the mannose receptor on monocyte-derived dendritic cells activates an anti-inflammatory immunosuppressive program. J Immunol. 2003;171:4552–4560.
- Shreffler WG, Castro RR, Kucuk ZY, Charlop-Powers Z, Grishina G, et al. The major glycoprotein allergen from Arachis hypogaea, Ara h 1, is a ligand of dendritic cell-specific ICAM-grabbing nonintegrin and acts as a Th2 adjuvant in vitro. J Immunol. 2006;177:3677–3685.
- Luong M, Lam JS, Chen J, Levitz SM. Effects of fungal N- and O-linked mannosylation on the immunogenicity of model vaccines. Vaccine. 2007;25:4340–4344.
- Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, et al. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem. 1990;265:10373–10382.
- Geijtenbeek TB, Van Vliet SJ, Koppel EA, Sanchez-Hernandez M, Vandenbroucke-Grauls CM, et al. Mycobacteria target DC-SIGN to suppress dendritic cell function. J Exp Med. 2003;197:7–17.
- Nigou J, Gilleron M, Rojas M, Garcia LF, Thurnher M, et al. Mycobacterial lipoarabinomannans: modulators of dendritic cell function and the apoptotic response. Microbes Infect. 2002;4:945–953.
- Smits HH, Engering A, van der Kleij D, de Jong EC, Schipper K, et al. Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Allergy Clin Immunol. 2005;115:1260–1267.
- Pulendran B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol Rev. 2004;199:227–250.
- Song XT, Evel-Kabler K, Rollins L, Aldrich M, Gao F, et al. An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. PLoS Med. 2006;3:e11. doi: .
- Li Y, Chu N, Rostami A, Zhang GX. Dendritic cells transduced with SOCS-3 exhibit a tolerogenic/DC2 phenotype that directs type 2 Th cell differentiation in vitro and in vivo. J Immunol. 2006;177:1679–1688.
- Popovic M, Tenner-Racz K, Pelser C, Stellbrink HJ, van Lunzen J, et al. Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 2005;102:14807–14812.
- Chougnet C, Gessani S. Role of gp120 in dendritic cell dysfunction in HIV infection. J Leukoc Biol. 2006;80:994–1000.
- Krathwohl MD, Schacker TW, Anderson JL. Abnormal presence of semimature dendritic cells that induce regulatory T cells in HIV-infected subjects. J Infect Dis. 2006;193:494–504.
- Norris PJ, Pappalardo BL, Custer B, Spotts G, Hecht FM, et al. Elevations in IL-10, TNF-alpha, and IFN-gammafrom the Earliest Point of HIV Type 1 Infection. AIDS Res Hum Retroviruses. 2006;22:757–762.
- Klenerman P, Ludewig B. Virus scores a perfect 10. Nat Med. 2006;12:1246–1248.
- Ejrnaes M, Filippi CM, Martinic MM, Ling EM, Togher LM, et al. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med. 2006;203:2461–2472.
- Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, et al. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med. 2006;12:1301–1309.
- Melar M, Ott DE, Hope TJ. Physiological levels of virion-associated human immunodeficiency virus type 1 envelope induce coreceptor-dependent calcium flux. J Virol. 2007;81:1773–1785.
- Buge SL, Ma HL, Amara RR, Wyatt LS, Earl PL, et al. Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge. AIDS Res Hum Retroviruses. 2003;19:891–900.
- Staprans SI, Barry AP, Silvestri G, Safrit JT, Kozyr N, et al. Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci U S A. 2004;101:13026–13031.
- Hammond SA, Raabe ML, Issel CJ, Montelaro RC. Evaluation of antibody parameters as potential correlates of protection or enhancement by experimental vaccines to equine infectious anemia virus. Virology. 1999;262:416–430.
- Raabe ML, Issel CJ, Cook SJ, Cook RF, Woodson B, et al. Immunization with a recombinant envelope protein (rgp90) of EIAV produces a spectrum of vaccine efficacy ranging from lack of clinical disease to severe enhancement. Virology. 1998;245:151–162.
- Wang SZ, Rushlow KE, Issel CJ, Cook RF, Cook SJ, et al. Enhancement of EIAV replication and disease by immunization with a baculovirus-expressed recombinant envelope surface glycoprotein. Virology. 1994;199:247–251.
- Liu M, Chen H, Luo F, Li P, Pan Q, et al. Deletion of N-glycosylation sites of hepatitis C virus envelope protein E1 enhances specific cellular and humoral immune responses. Vaccine. 2007;25:6572–6580.
- Halary F, Amara A, Lortat-Jacob H, Messerle M, Delaunay T, et al. Human cytomegalovirus binding to DC-SIGN is required for dendritic cell infection and target cell trans-infection. Immunity. 2002;17:653–664.
- Lambert DM. Role of oligosaccharides in the structure and function of respiratory syncytial virus glycoproteins. Virology. 1988;164:458–466.
- Lin G, Simmons G, Pohlmann S, Baribaud F, Ni H, et al. Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR. J Virol. 2003;77:1337–1346.
- Beddows S, Kirschner M, Campbell-Gardener L, Franti M, Dey AK, et al. Construction and characterization of soluble, cleaved, and stabilized trimeric Env proteins based on HIV type 1 Env subtype A. AIDS Res Hum Retroviruses. 2006;22:569–579.
- Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci U S A. 2002;99:395–400.
- Donzella GA, Schols D, Lin SW, Este JA, Nagashima KA, et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med. 1998;4:72–77.
- Allaway GP, Davis-Bruno KL, Beaudry GA, Garcia EB, Wong EL, et al. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses. 1995;11:533–539.
- Roben P, Moore JP, Thali M, Sodroski J, Barbas CF, III, et al. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol. 1994;68:4821–4828.
- Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol. 1996;70:1100–1108.
- Moore JP, McCutchan FE, Poon SW, Mascola J, Liu J, et al. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J Virol. 1994;68:8350–8364.
- Geijtenbeek TB, Torensma R, van Vliet SJ, van Duijnhoven GC, Adema GJ, et al. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell. 2000;100:575–585.
- Mosca PJ, Hobeika AC, Clay TM, Nair SK, Thomas EK, et al. A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment. Blood. 2000;96:3499–3504.
- Lyons AB. Analyzing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods. 2000;243:147–154.
Source: PubMed